FDA Approves Merck's WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone

Related Keywords

Canada ,Paris ,France General ,France ,United States ,Saclay ,Marc Humbert ,Aaron Waxman ,Matt Granato ,Eliav Barr ,Bristol Myers Squibb ,Merck Research Laboratories ,Pulmonary Hypertension Reference Center ,World Health Organization Group ,Drug Administration ,Merck Access Program ,Pulmonary Hypertension Association ,World Health Organization ,Breakthrough Therapy Designation ,Pulmonary Hypertension ,Executive Director ,Pulmonary Heart Diseases ,Merck Research ,Merck Access ,Minute Walk Distance ,Bristol Myers ,